Better Science, Better Health: New Trial Pathways and Better Patient Data

New Pathways for Development and Better Patient Outcomes

• Stephen Whitehead, Chief Executive, ABPI

New Pathways & New Sources of Evidence. What do we need?

• Marc Trusheim, MIT Sloan School of Management
• Finn Børlum Kristensen, Executive Director, Eunetha
• Jillian Oderkirk, Senior Analyst, Health Division, OECD

High Quality Patient Data and MAPPs; Better Patient Outcomes, Faster and Cheaper

• Duane Schulthess, Managing Director, Vital Transformation
• Mohammad Al-Ubaydli, CEO, Patients Know Best
• Joel Haspel, Director Strategy & Business Development EMEA, Oracle Health Sciences

Blazing Trails – New Development Pathways in Action

• Sandrine Marreaud, Head of Medical and Pharmacovigilance Department, EORTC
• Ryan Hohman, Managing Director, Friends of Cancer Research
• Laura Esserman, Breast Cancer Center Director (I-Spy), University of California San Francisco
• James Anderson, Director of EU Industry & External Partnerships, GSK
• Edward Abrahams, President, Personalized Medicine Coalition (Moderator)

Real World Evidence – What works?

• Ifty Ahmed, CEO, Pow Health
• John Crawford, Healthcare Industry Leader, IBM Europe
• Geoff Wilson, HTA Task Force Leader, COCIR

The Patient’s Understanding of Benefit Risk

• Pat Furlong, CEO, Parent Project Muscular Dystrophy
• Sarah Garner, National Institutes of Clinical Excellence
• Andrea Beyer, Expert Benefit Risk Assessment
• Bettina Ryll, Founder, Melanoma Patient Network Europe

IMI2: Putting MAPPs Into Practice in Europe

• Jeremy Haigh, European Chief Operating Officer, Research & Development, Amgen Ltd.